For research use only. Not for therapeutic Use.
ABT-751（Cat No.:I001578）is an investigational small molecule that acts as an antitumor agent, primarily designed to inhibit microtubule dynamics. It demonstrates potent activity against various cancer cell lines by disrupting the normal function of microtubules, which are crucial for cell division. By preventing microtubule assembly, ABT-751 induces cell cycle arrest and apoptosis in cancer cells. Its selective action makes it a promising candidate for targeted cancer therapy, particularly in solid tumors. Ongoing clinical trials are evaluating its efficacy and safety, with hopes of positioning ABT-751 as an effective treatment option in oncology.
| Catalog Number | I001578 |
| CAS Number | 141430-65-1 |
| Synonyms | N-[2-(4-hydroxyanilino)pyridin-3-yl]-4-methoxybenzenesulfonamide |
| Molecular Formula | C₁₈H₁₇N₃O₄S |
| Purity | ≥95% |
| Target | Microtubule/Tubulin |
| Solubility | DMSO: ≥ 48 mg/mL |
| Storage | under inert gas (nitrogen or Argon) at 2–8 °C |
| IC50 | 1.5 μM(neuroblastoma); 3.4 μM(non-neuroblastoma) |
| IUPAC Name | N-[2-(4-hydroxyanilino)pyridin-3-yl]-4-methoxybenzenesulfonamide |
| InChI | InChI=1S/C18H17N3O4S/c1-25-15-8-10-16(11-9-15)26(23,24)21-17-3-2-12-19-18(17)20-13-4-6-14(22)7-5-13/h2-12,21-22H,1H3,(H,19,20) |
| InChIKey | URCVCIZFVQDVPM-UHFFFAOYSA-N |
| SMILES | COC1=CC=C(C=C1)S(=O)(=O)NC2=C(N=CC=C2)NC3=CC=C(C=C3)O |
| Reference | </br>1:Reactive Oxygen Species Mediates the Synergistic Activity of Fenretinide Combined with the Microtubule Inhibitor ABT-751 against Multidrug-Resistant Recurrent Neuroblastoma Xenografts. Chen NE, Maldonado NV, Khankaldyyan V, Shimada H, Song MM, Maurer BJ, Reynolds CP.Mol Cancer Ther. 2016 Nov;15(11):2653-2664. Epub 2016 Aug 16. PMID: 27530131 </br>2:A microtubule inhibitor, ABT-751, induces autophagy and delays apoptosis in Huh-7 cells. Wei RJ, Lin SS, Wu WR, Chen LR, Li CF, Chen HD, Chou CT, Chen YC, Liang SS, Chien ST, Shiue YL.Toxicol Appl Pharmacol. 2016 Nov 15;311:88-98. doi: 10.1016/j.taap.2016.09.021. Epub 2016 Sep 24. PMID: 27678524 </br>3:Synthesis and Biological Evaluation of N-[2-(4-Hydroxyphenylamino)-pyridin-3-yl]-4-methoxy-benzenesulfonamide (ABT-751) Tricyclic Analogues as Antimitotic and Antivascular Agents with Potent in Vivo Antitumor Activity. Segaoula Z, Leclercq J, Verones V, Flouquet N, Lecoeur M, Ach L, Renault N, Barczyk A, Melnyk P, Berthelot P, Thuru X, Lebegue N.J Med Chem. 2016 Sep 22;59(18):8422-40. doi: 10.1021/acs.jmedchem.6b00847. Epub 2016 Aug 30. PMID: 27538123 </br>4:Phase 1 Study of ABT-751 in Combination With CAPIRI (Capecitabine and Irinotecan) and Bevacizumab in Patients With Advanced Colorectal Cancer. Rudek MA, Dasari A, Laheru D, He P, Jin R, Walker R, Taylor GE, Jimeno A, Donehower RC, Hidalgo M, Messersmith WA, Purcell WT.J Clin Pharmacol. 2016 Aug;56(8):966-73. doi: 10.1002/jcph.681. Epub 2016 Feb 2. PMID: 26632033 Free PMC Article</br>5:Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-751: a report from the Children/’s Oncology Group (ANBL0621). Fox E, Mosse/’ YP, Meany HM, Gurney JG, Khanna G, Jackson HA, Gordon G, Shusterman S, Park JR, Cohn SL, Adamson PC, London WB, Maris JM, Balis FM.Pediatr Blood Cancer. 2014 Jun;61(6):990-6. doi: 10.1002/pbc.24900. Epub 2013 Dec 18. PMID: 24347462 Free PMC Article</br>6:Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development: the example of the novel anticancer agent ABT-751. Innocenti F, Ramírez J, Obel J, Xiong J, Mirkov S, Chiu YL, Katz DA, Carr RA, Zhang W, Das S, Adjei A, Moyer AM, Chen PX, Krivoshik A, Medina D, Gordon GB, Ratain MJ, Sahelijo L, Weinshilboum RM, Fleming GF, Bhathena A.Pharmacogenet Genomics. 2013 Jul;23(7):374-81. doi: 10.1097/FPC.0b013e3283623e81. PMID: 23670235 Free PMC Article</br>7:A phase I trial and in vitro studies combining ABT-751 with carboplatin in previously treated non-small cell lung cancer patients. Ma T, Fuld AD, Rigas JR, Hagey AE, Gordon GB, Dmitrovsky E, Dragnev KH.Chemotherapy. 2012;58(4):321-9. doi: 10.1159/000343165. Epub 2012 Nov 12. PMID: 23147218 Free PMC Article</br>8:ABT-751 in relapsed childhood acute lymphoblastic leukemia. Gaynon PS, Harned TM; Therapeutic Advances in Childhood Leukemia/Lymphoma Consortium..J Pediatr Hematol Oncol. 2012 Oct;34(7):583-4. No abstract available. PMID: 22584778 </br>9:Evaluation of the oral antimitotic agent (ABT-751) in dogs with lymphoma. Silver M, Rusk A, Phillips B, Beck E, Jankowski M, Philibert J, Hahn K, Hershey E, McKeegan E, Bauch J, Krivoshik A, Khanna C.J Vet Intern Med. 2012 Mar-Apr;26(2):349-54. doi: 10.1111/j.1939-1676.2012.00892.x. Epub 2012 Feb 28. PMID: 22369215 Free Article</br>10:Phase I/II study of pemetrexed with or without ABT-751 in advanced or metastatic non-small-cell lung cancer. Rudin CM, Mauer A, Smakal M, Juergens R, Spelda S, Wertheim M, Coates A, McKeegan E, Ansell P, Zhou X, Qian J, Pradhan R, Dowell B, Krivoshik A, Gordon G.J Clin Oncol. 2011 Mar 10;29(8):1075-82. doi: 10.1200/JCO.2010.32.5944. Epub 2011 Feb 7. PMID: 21300929 Free PMC Article |
